Navigation Links
Takeda Receives New Information on Alogliptin (SYR-322) NDA
Date:3/6/2009

OSAKA, Japan, March 6 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, was informed as part of regular discussions about the alogliptin New Drug Application (NDA) with the United States Food and Drug Administration (FDA), that although the alogliptin NDA was filed prior to issuance of FDA's December 2008 guidance on new Type 2 diabetes treatments, the FDA will apply these guidelines when reviewing the alogliptin NDA.

Additionally, the FDA does not believe that the amount of existing alogliptin clinical data is sufficient to meet certain statistical requirements in the new guidance. The agency is open to discussions regarding the design of additional CV studies with alogliptin. Alogliptin's Prescription Drug User Fee Act (PDUFA) date - June 26, 2009 - remains unchanged.

In December, 2008 the FDA issued "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes".

In October 2008, Takeda received notification from the FDA that it was unable to complete its review of the alogliptin NDA by the original PDUFA date -- October 27, 2008 -- due to internal resource constraints. The FDA did not raise any issues with the data in the alogliptin NDA at that time. In December 2007, Takeda submitted its NDA for alogliptin to the FDA.

Alogliptin, which was discovered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor being reviewed as an adjunct to diet and exercise for the treatment of type 2 diabetes.

About DPP-4 Inhibitors

DPP-4 inhibitors inhibit the enzyme dipeptidyl peptidase IV (DPP-4), which metabolizes the insulin-increasing hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
2. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
3. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
4. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
5. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
6. Takeda Completes Acquisition of Millennium
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. Takeda Announces New U.S. Leadership
10. Takeda submits new drug application for alogliptin (syr-322) in the US
11. Chemizon Announces Research Collaboration Expansion With Takeda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... GA (PRWEB) August 20, 2014 ... to healthcare, Jvion successfully predicted stage iii and ... that, in some situations, approached 90%. A company ... been achieved in commercial or academic settings. The ... prevent all types of hospital-acquired conditions to help ...
(Date:8/20/2014)... Oshkosh, Wisconsin (PRWEB) August 20, 2014 ... to the general public at fair prices. The well-known ... ability, and she is now touring in 19 cities, ... locations where the television personality will visit are Albany, ... Kalamazoo, Colorado Springs, Albuquerque, Beverly Hills and San Diego. ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... August 20, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers,restraints, challenges, opportunities, current market trends,and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:8/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sodium Chloride IV . ... lot of Sodium Chloride IV 0.9%, USP 1000 mL, by ... presence of particulate matter. Sodium Chloride Injection, USP is used ... priming solution in hemodialysis procedures. , The reason ...
Breaking Medicine News(10 mins):Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. 3 ... detect prostate cancer and better evaluate a patient,s treatment options, ... their physician can use to help them decide whether it,s ... said lead researcher Dr. Scott Tomlins, a pathology resident at ...
... , WEDNESDAY, Aug. 3 (HealthDay News) -- Many Americans believe ... is, a new survey finds. The telephone poll of ... be like a video camera that records detailed information for ... the participants believed that once experiences are stored as memory, ...
... , Arriving at a rapid and accurate diagnosis is critical ... officials have had to choose between a highly accurate yet ... new detection method developed at the University of Georgia and ... however, offers the best of both worlds. By coating ...
... Mayo Clinic orthopedic surgeon suspects that the nagging pain ... may be different from what men encounter, and she ... to explore the question. The Society for Women,s Health ... Network on Musculoskeletal Health has awarded a group of ...
... News) -- Vampire bats have heat-detecting molecules that help guide ... long been known that vampire bats know where to bite ... a vein, but the researchers believe this is the first ... Venezuelan researchers investigated wild vampire bats in South America and ...
... ranging from artificial hip joints to dentures and catheters, become ... called biofilms that are resistant to the human immune system ... However, researchers may have a new way of looking ... Iowa biologist David Soll and his colleagues published in the ...
Cached Medicine News:Health News:Urine Test Might Help Predict Prostate Cancer Risk 2Health News:Urine Test Might Help Predict Prostate Cancer Risk 3Health News:Memories Can Be Unreliable, Manipulated 2Health News:UGA researchers use gold nanoparticles to diagnose flu in minutes 2Health News:UGA researchers use gold nanoparticles to diagnose flu in minutes 3Health News:Mayo Clinic examines why knee osteoarthritis afflicts more women than men 2
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
(Date:8/19/2014)... YORK , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage ... will present a scientific poster describing an innovative diagnostic ... SPEC 2014: Shedding New Light on Disease (SPEC) conference ... Dr. Treado,s poster entitled, "Development of in vitro ... Imaging" will be discussed during the conference poster session ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp Inc. ... funding round led by Walden Riverwood Ventures with ... development of Atonarp,s Smart Spectrometer technology platform, which ... company has targeted the oil & gas and ... "We are excited to partner with Atonarp in ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2
... China Botanic Pharmaceutical Inc. (AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... the Company,s new Chief Financial Officer ("CFO") on December ... over 10 years with key positions in finance, audit, ...
... Calif. and LUXEMBOURG, Dec. 16, 2010 WaferGen Biosystems, ... leading developer of state-of-the-art genomic analysis systems, and the ... to establish a strategic relationship that will expand the ... Europe and advance personalized medicine.   The ...
Cached Medicine Technology:China Botanic Appoints David Dong as New Chief Financial Officer 2China Botanic Appoints David Dong as New Chief Financial Officer 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: